Synergy Pharmaceuticals begins Phase IIb trial of Plescanatide in IBS-C Synergy Pharmaceuticals (SGYP) announced that dosing has commenced in a Phase IIb clinical trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome, or IBS-C. This trial is being conducted at 70 sites in the U.S. and includes 350 patients with IBS-C who will be treated with one of four doses of plecanatide or placebo, taken once daily over a period of 12 weeks. PAREXEL International (PRXL) is the Contract Research Organization for the trial.
News For SGYP;PRXL From The Last 14 Days
Check below for free stories on SGYP;PRXL the last two weeks.
Subscribe for More Information